Ronald K Knickerbocker

Learn More
CONTEXT Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known. OBJECTIVE To determine the effect of raloxifene therapy on risk of vertebral and nonvertebral fractures. DESIGN The Multiple Outcomes of Raloxifene Evaluation (MORE)(More)
Raloxifene is a selective estrogen receptor modulator that in experimental animals acts as an estrogen receptor antagonist in breast and endometrium but as an estrogen receptor agonist in the skeletal and cardiovascular systems. We conducted a 1-year prospective, randomized, double-blind trial in 143 postmenopausal osteoporotic women (mean +/- SD age,(More)
Ponatinib is approved for adults with refractory chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia, including those with the T315I BCR-ABL1 mutation. We pooled data from 3 clinical trials (N=671) to determine the impact of ponatinib dose intensity on the following adverse events: arterial occlusive events(More)
We consider a semiparametric estimation method for general regression models when some of the predictors are measured with error. The technique relies on a kernel regression of the \true" covariate on all the observed covariates and surrogates. This requires a nonparametric regression in as many dimensions as there are covariates and surrogates. The usual(More)
  • 1